Opioid Reduced Anesthesia in Major Oncologic Cervicofacial Surgery: A Retrospective Study.

Area of Science:

• Anesthesiology
• Oncologic Surgery
• Perioperative Medicine

Background:

• Opioid sparing is a key challenge in anesthesia and perioperative care.
• Opioid-reduced anesthesia (ORA) utilizes multimodal analgesia with non-opioid and regional techniques to minimize intraoperative opioid use.
• Major cervicofacial oncologic surgery presents significant postoperative pain and pulmonary complication risks, making it a potential candidate for ORA.

Purpose of the Study:

• To evaluate the efficacy of opioid-reduced anesthesia (ORA) in major cervicofacial oncologic surgery.
• To compare perioperative opioid consumption and postoperative pain scores between ORA and standard opioid-based anesthesia.
• To assess opioid-related side effects and pulmonary complications in both groups.

Main Methods:

• Retrospective case-controlled study of 172 patients undergoing major cervicofacial oncologic surgery.
• Group ORA (n=86) received dexmedetomidine and lidocaine, compared to a control group (n=86) receiving standard opioid-based anesthesia.
• Primary endpoints included perioperative opioid consumption and postoperative pain scores; secondary endpoints were opioid-related side effects.

Main Results:

• The ORA group received significantly less intraoperative morphine (6.2 mg vs 10.1 mg).
• No significant differences were observed in postoperative analgesia requirements or pain scores between groups.
• The ORA group showed a potential reduction in hypoxemia (50% vs 70%) and need for pressure-assisted ventilation (6% vs 19%), but experienced more bradycardia (4 vs 2 patients).

Conclusions:

• ORA did not reduce postoperative pain or opioid requirements in this study.
• ORA may potentially decrease hypoxemia and the need for additional ventilation, but confounding factors cannot be excluded.
• Prospective studies are necessary to confirm the potential benefits of ORA in major cervicofacial oncologic surgery.